Skip to main content
Nautilus Biotechnology, Inc. logo

Nautilus Biotechnology, Inc. — Investor Relations & Filings

Ticker · NAUT ISIN · US63909J1088 US Professional, scientific and technical activities
Open in API
Filings indexed 299 across all filing types
Latest filing 2023-02-13 Major Shareholding Noti…
Country US United States of America
Listing US NAUT

About Nautilus Biotechnology, Inc.

https://www.nautilus.bio/

Nautilus Biotechnology, Inc. is a life sciences company developing a platform to revolutionize proteome analysis. The company's Proteome Analysis Platform is designed to quantify proteins at the single-molecule level, leveraging a proprietary method called Iterative Mapping. This technology aims to provide high-resolution views of billions of individual protein molecules and their modifications (proteoforms). The platform is being developed with two key modalities: broadscale proteomic analysis for comprehensive proteome exploration and targeted proteoform analysis for in-depth examination of protein variants. The intended applications include accelerating drug target identification, discovering more effective biomarkers, and enabling foundational biological research by making advanced proteomics more accessible to the scientific community.

Recent filings

Filing Released Lang Actions
SC 13G
Major Shareholding Notification
2023-02-13 English
10-Q
Interim / Quarterly Report 9M 2022
2022-11-01 English
8-K/A
Board/Management Information Classification · 95% confidence The document is a Form 8-K/A filed with the SEC, specifically an amendment to a current report. The content focuses on the appointment of a new director to the Board of Directors and her subsequent appointment to a Board committee. There are no financial statements, earnings data, or detailed management discussion. The primary subject is changes in the company's board composition and committee membership. This fits the category of Board/Management Information (MANG). The document length is 3619 characters, which is relatively short and consistent with a management change announcement rather than a full report. Therefore, the classification is MANG with high confidence.
2022-10-31 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Nautilus Biotechnology, Inc. It includes an Item 2.02 reporting financial results for the quarter ended September 30, 2022, referencing a press release attached as Exhibit 99.1. The document also includes Item 5.03 describing amendments to the company's bylaws, and Item 9.01 listing exhibits including the amended bylaws and the press release. The key financial information is provided via a press release, not a full quarterly report with detailed financial statements. The document is primarily an announcement of financial results and corporate governance changes, typical of an 8-K filing. Given the presence of a press release reporting quarterly financial results, this aligns best with an Earnings Release (ER) classification. The document length (5160 characters) and content support this classification rather than a full Interim/Quarterly Report (IR).
2022-10-31 English
FORM 4
Director's Dealing
2022-09-28 English
FORM 4
Director's Dealing
2022-09-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.